Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.73 USD
Change Today -0.0747 / -9.28%
Volume 7.0M
XOMA On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

xoma corp (XOMA) Snapshot

Open
$0.80
Previous Close
$0.81
Day High
$0.82
Day Low
$0.73
52 Week High
11/28/14 - $5.95
52 Week Low
07/31/15 - $0.73
Market Cap
86.1M
Average Volume 10 Days
17.3M
EPS TTM
$-0.50
Shares Outstanding
117.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for XOMA CORP (XOMA)

Related News

No related news articles were found.

xoma corp (XOMA) Related Businessweek News

No Related Businessweek News Found

xoma corp (XOMA) Details

XOMA Corporation discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific. The company’s lead product candidate includes gevokizumab, a proprietary humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta, which is in Phase III clinical trial for NIU and Behçet’s disease uveitis, pyoderma gangrenosum, active non-infectious anterior scleritis, autoimmune inner ear disease, and cardiovascular diseases, as well as diseases under the neutrophilic dermatoses designation, Schnitzler syndrome, and other diseases; and various proof-of-concept studies comprising polymyositis/dermatomyositis, Schnitzler syndrome, and giant cell arteritis. Its proprietary product pipeline also comprises XOMA metabolic activating, sensitizing, and deactivating/antagonizing antibodies that are in preclinical stage for the treatment of diabetes patients; XOMA 3AB, a multi-antibody product for the treatment of human botulism poisoning; and XOMA 629, a topical anti-bacterial product for the treatment of human immune system. In addition, the company licenses antibody discovery, optimization, and development technologies, including Antibody Discovery Advanced Platform Technologies, ModulX, and OptimX. It has collaboration and licensing agreements with Les Laboratoires Servier; National Institute of Allergy and Infectious Diseases; Takeda Pharmaceutical Company Limited; Novartis AG; Pfizer Inc.; Symplmed Pharmaceuticals, LLC; and Texas A&M University. The company was founded in 1981 and is headquartered in Berkeley, California.

181 Employees
Last Reported Date: 05/7/15
Founded in 1981

xoma corp (XOMA) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $569.5K
Founder, Chief Scientific Officer, Executive ...
Total Annual Compensation: $250.3K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $411.0K
Chief Commercial Officer and Vice President
Total Annual Compensation: $391.4K
Compensation as of Fiscal Year 2014.

xoma corp (XOMA) Key Developments

Rigrodsky & Long, P.A. Files Securities Fraud Class Action Lawsuit against XOMA Corporation

Rigrodsky & Long, P.A. announced that a complaint has been filed in the United States District Court for the Northern District of California on behalf of all persons or entities that purchased the common stock of XOMA Corporation between November 6, 2014 and July 21, 2015, inclusive, alleging violations of the Securities Exchange Act of 1934 against the company and certain of its officers. The complaint alleges that throughout the Class Period, defendants made materially false and misleading statements, and omitted materially adverse facts, about the Company's business, operations and prospects.  As a result of defendants' alleged false and misleading statements, the Company's stock traded at artificially inflated prices during the Class Period. According to the Complaint, on July 22, 2015, the Company revealed that the EYEGUARD-B study for its lead product candidate, gevokizumab, did not meet the primary endpoint of first acute ocular exacerbation.

XOMA Corporation - Special Call

To discuss the results from phase 3 EYEGUARD(TM)-B study

XOMA Corporation Receives Orphan Drug Designation for XOMA 358 From U.S. FDA for Treatment of Congenital Hyperinsulinism

XOMA Corporation announced XOMA 358, a fully human allosteric monoclonal antibody that reduces both the binding of insulin to its receptor and downstream insulin signaling, has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of congenital hyperinsulinism (HI). Orphan drug designation is granted by the FDA Office of Orphan Products Development (OOPD) to novel drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the United States. The designation provides the drug developer with a seven-year period of U.S. marketing exclusivity, as well as tax credits for clinical research costs, the ability to apply for annual grant funding, clinical research trial design assistance, and waiver of Prescription Drug User Fee Act (PDUFA) filing fees. The OOPD also works on rare disease issues with the medical and research communities, professional organizations, academia, governmental agencies, industry, and rare disease patient groups.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XOMA:US $0.73 USD -0.0747

XOMA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
arGEN-X BV €11.01 EUR 0.00
BioInvent International AB kr2.61 SEK -0.03
Genmab A/S kr644.00 DKK +4.50
MorphoSys AG €73.77 EUR +0.87
PDL BioPharma Inc $5.82 USD +0.06
View Industry Companies
 

Industry Analysis

XOMA

Industry Average

Valuation XOMA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.7x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact XOMA CORP, please visit www.xoma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.